Houston, TX (July 9, 2019) – Procyrion, Inc., a clinical-stage medical device company, today announced the completion of a $30 million Series D funding round led by a new investor, Bluebird Ventures. Returning investors include Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. The company is developing its Aortix™ system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function (cardiorenal syndrome). The investment will fund the company’s pilot study through the activities needed to support the submission of an FDA IDE application for its pivotal trial. To date, Procyrion has raised more than $59 million in funding.
“Of the more than 1 million patients per year in the U.S. admitted to the hospital with acute decompensated heart failure, 25–30% also have…